PROCEPT BioRobotics Corporation reported a revenue of $83.1 million for the first quarter of 2026, marking a 20% increase from $69.2 million in the same period of 2025. The growth was primarily driven by higher sales volumes of system sales, handpieces, and service contracts, particularly in the U.S. market, which accounted for approximately 87% of total revenue. Despite the revenue increase, the company recorded a net loss of $31.6 million, compared to a net loss of $24.7 million in the prior year, reflecting a 28% increase in losses attributed to rising operating expenses.
Total operating expenses rose to $86.6 million, up from $71.6 million in the previous year, with significant increases in both research and development (R&D) and selling, general, and administrative (SG&A) expenses. R&D expenses increased by 31% to $21.5 million, driven by higher employee-related costs associated with ongoing product development. SG&A expenses also rose by 18% to $65.1 million, reflecting investments in expanding the commercial organization to support revenue growth.
As of March 31, 2026, PROCEPT BioRobotics had an install base of 971 robotic systems globally, including 765 in the United States. The company aims to increase system utilization by targeting hospitals that perform resective procedures for benign prostatic hyperplasia (BPH). The company’s AquaBeam and HYDROS robotic systems are designed to provide effective treatment for BPH, and the company has established strong relationships with key opinion leaders in the urology community to facilitate broader adoption of its technology.
The company’s cash and cash equivalents stood at $245.6 million, down from $286.5 million at the end of 2025. The decrease in cash was primarily due to net cash used in operating activities, which totaled $38.1 million for the quarter. PROCEPT BioRobotics continues to invest in its sales and marketing efforts, as well as in R&D, to drive future growth. The company anticipates that its existing cash reserves and projected revenue will be sufficient to meet its capital requirements for at least the next twelve months, although it may seek additional financing if necessary.
Looking ahead, PROCEPT BioRobotics is focused on expanding its market presence and increasing the adoption of its Aquablation therapy. The company plans to enhance its sales force and continue to build on its clinical evidence to support reimbursement discussions with third-party payors. The management remains optimistic about the potential for revenue growth as it aims to establish Aquablation therapy as the standard of care for BPH treatment.
About PROCEPT BioRobotics Corp
Procept Biorobotics develops advanced surgical robotic systems for minimally invasive urologic procedures, primarily treating benign prostatic hyperplasia (BPH). Its flagship products, AquaBeam and HYDROS systems, utilize proprietary waterjet technology for precise, safe, and durable tissue removal. The company targets hospitals and urologists worldwide, emphasizing clinical evidence, personalized treatment planning, and broad reimbursement support to improve patient outcomes and establish a new standard in BPH surgery.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.